Birchview Capital, LP Alkermes Plc. Transaction History
Birchview Capital, LP
- $111 Million
- Q1 2025
A detailed history of Birchview Capital, LP transactions in Alkermes Plc. stock. As of the latest transaction made, Birchview Capital, LP holds 50,000 shares of ALKS stock, worth $1.34 Million. This represents 1.49% of its overall portfolio holdings.
Number of Shares
50,000
Previous 50,000
-0.0%
Holding current value
$1.34 Million
Previous $1.44 Million
14.81%
% of portfolio
1.49%
Previous 1.23%
Shares
2 transactions
Others Institutions Holding ALKS
# of Institutions
407Shares Held
176MCall Options Held
229KPut Options Held
436K-
Black Rock Inc. New York, NY29.1MShares$777 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.2MShares$486 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11.8MShares$315 Million0.05% of portfolio
-
State Street Corp Boston, MA8.02MShares$214 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY6.88MShares$184 Million3.72% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.39B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...